CRISPR Therapeutics AG

Youtube Subscribe

Open: 53.28 Close: 50.95 Change: -2.33

Our AI found some flaws in CRISPR Therapeutics AG Stock.

How much time have you spent trying to decide whether investing in CRISPR Therapeutics AG? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about CRISPR Therapeutics …

Concept Map

Semantic Network

Stock Summary

CRISPR Therapeutics AG focuses on developing gene-based medicines for serious diseases. Its lead product candidate is CTX001, an ex vivo CRISpr gene-edited therapy for treating patients suffering from transfusion-dependent beta.

Today's Summary

CRISPR Therapeutics AG (CRSP) added 10% Tuesday on above-average volumes after the gene-editing company announced better-than-expected financials.

Today's News

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISpr/Cas9 platform. CRISSP shares currently sit at 50.95 USD today. CRSP shares are rated a Sell. CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Mirae Asset Global Investments Co. increased its position in CRISpr Therapeutic AG by 4.6% in the 1st quarter. Spire Wealth Management boosted its stake in CRisPR Therapies by 101.8% during the second quarter. CRISPR Therapeutics AG (CRSP) added 10% Tuesday on above-average volumes after the gene-editing company announced better-than-expected Q2 2023 financials. Equity analysts have taken note of these positive figures and predict that CRISpr Therapeutic company will post a projected EPS of -6.37 for the current fiscal year. CRISPR Therapeutics AG (CRSP, $50.96) RSI Indicator left the oversold zone on August 04, 2023 Tickeron - Technical Analysis. RBC Capital analyst Luca Issi maintained a Hold rating. Crispr Therapeutics AG (CRSP) currently carries a Zacks Rank #3 (Hold) Post the announcement, CRISPR Therapeutic shares inched up 1.6%. CRISPR Therapeutics AGs solvency score is77/100. Wall Street analysts forecast CRSP stock price to rise over the next 12 months. During the last12 months, CRSP insidershave not bought any shares,and sold 13.1M USD worth of shares.

Stock Profile

"CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland."

Keywords

The game is changing. There is a new strategy to evaluate CRISPR Therapeutics AG fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about CRISPR Therapeutics AG are: CRISPR, Therapeutics, AG, CRSP, share, company, Therapeutic, and the most common words in the summary are: therapeutic, state, crispr, united, stock, system, gene, . One of the sentences in the summary was: CRISPR Therapeutics AG (CRSP) added 10% Tuesday on above-average volumes after the gene-editing company announced better-than-expected financials.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #state #crispr #united #stock #system #gene.

Read more →

Youtube Subscribe

---